<DOC>
	<DOCNO>NCT01603121</DOCNO>
	<brief_summary>The primary goal study investigate safety tolerability investigational drug lisofylline , administer skin vein , people type 1 diabetes . A second aim determine much drug available blood injection skin , compare injection vein .</brief_summary>
	<brief_title>Lisofylline Continuous Subcutaneous Intravenous Administration Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>This open-label , randomize , crossover study subject type 1 diabetes . There two treatment period separate approximately one week . One treatment consist 10 hour subcutaneous infusion lisofylline , treatment consist 10 hour intravenous infusion lisofylline . Eligible subject admit Infusion Center morning dosing ( Day 1 , Day 7 ) treatment period , receive assign dose study drug Day 1 Day 7 , remain confined Infusion Center approximately 3 hour follow start study drug administration remain blood draw . The subject escort Sleep Center Eastern Virginia Medical School overnight stay time heart rate oxygen saturation monitor pulse oximetry . The next morning subject return Infusion Center final blood draw physical examination . The Infusion Center Sleep Disorders Center within Sentara Norfolk General Hospital . All subject assign treatment sequence accord randomization schedule .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Lisofylline</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Male female adult age 18 45 year age Ability understand provide write informed consent Ability complete study compliance protocol If female , subject must nonpregnant nonlactating , willing use appropriate adequate contraception study If male , subject must willing use effective birth control study Weight least 50 kg ( 110 lb ) Body mass index 18.5 30 kg/m2 QTc &lt; 450 msec screen Clinical diagnosis type 1 diabetes least 2 year prior screen Treatment insulin least 1 year stable dose least 3 month prior screen ( dose must &lt; 0.8 units/kg/day ) Subjects must selfmonitor blood glucose level least daily HbA1c 69 % Serum cpeptide level &lt; 0.6 ng/mL Serum creatinine &lt; 1.5 mg/dL male &lt; 1.4 mg/dL female Negative hepatitis B , hepatitis C HIV test screen within 3 month screen Subjects must free clinically significant abnormal finding time screen ( include abnormality examination , medical history , electrocardiogram , clinical laboratory test ) ; determine principal investigator Subjects significant stomach , liver , kidney heart disease , include high blood pressure , stroke blood vessel disease . Significant eye problem due diabetes , diabetic nerve disease , nonhealed diabetic foot ulcer Personal family history long QTc syndrome History clinically significant change orthostatic blood pressure Clinically significant change orthostatic blood pressure screen History peptic ulcer disease and/or gastrointestinal bleeding/perforation History presence proliferative retinopathy , severe nonproliferative retinopathy , macular edema presence untreated diabetic eye disease History severe peripheral autonomic neuropathy opinion study physician History hypoglycemia unawareness , and/or episode severe hypoglycemia within 60 day screen Diagnosis type 2 diabetes , base upon subject report Use oral antihyperglycemic medication , pentoxyifylline , and/or theophylline Use drug therapy directly affect gastrointestinal motility History significant drug allergy History difficulty phlebotomy Use recreational drug within past year previous history drug alcohol abuse Positive result screen alcohol substance abuse screen upon admission study site Current smoker user tobacco product Use prescription medication acceptable Principal Investigator 's discretion part stable drug regimen document last 60 day . Drug therapy hold morning Day 1 Day 7 Principal Investigator 's discretion use overthecounter drug herbal preparation within 72 hour prior receive study drug Consumption caffeinecontaining food beverage within 24 hour prior receive study drug Consumption alcohol within 24 hour prior admission study site Consumption grapefruit grapefruitcontaining juice within 72 hour prior receive study drug Use investigational drug product , participation drug research study within 30 day prior receive drug Prior exposure lisofylline Donation blood ( 1 pint ) within 30 day plasma within 7 day receive study drug Any condition opinion study investigator would interfere participant 's ability provide inform consent , comply study instruction , possibly confound interpretation study result , endanger participant take part trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>lisofylline</keyword>
</DOC>